miércoles, 7 de octubre de 2026

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· July 21, 2026

GM releases 2026 second-quarter results, raises full-year 2026 guidance and declares quarterly dividend

View original at finance.yahoo.com

GM releases 2026 second-quarter results, raises full-year 2026 guidance and declares quarterly dividend DETROIT, July 21, 2026 /PRNewswire/ -- General Motors (NYSE: GM) today reported second-quarter 2026 revenue of $48.0 billion, net income attributable to stockholders of $1.3 billion, and EBIT-adjusted of $3.9 billion…

Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

GM is raising its full-year 2026 EBIT-adjusted guidance for the second time this year.
60% confidence
GM's Board of Directors declared a quarterly cash dividend of $0.18 per share, payable September 17, 2026, to holders of record as of September 4, 2026.
60% confidence
GM expects full-year 2026 net income attributable to stockholders of $8.4 billion to $9.8 billion, automotive operating cash flow of $15.4 billion to $19.4 billion, and EPS-diluted of $8.98 to $10.98.
60% confidence
These expected full-year 2026 financial results do not include the potential impact of future adjustments related to special items.
60% confidence

Lo que sabemos · la inteligencia detrás de esta página

En vivo desde el sustrato

Lo que estamos viendo

Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs

Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.

Nuestra lectura de los datos ›

Señales que seguimos

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patrones que observamos ›

Donde las fuentes discrepan

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

Señalamos los conflictos abiertamente ›

Verificado recientemente

✓ Verificado con la fuente original

4,986

hechos rastreados a su fuente — y señalamos los que no se sostienen.

101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados

Consulta estos datos → isubstrate.com